Linfomas
GLUN
![Foto de Linfomas](/img/uploaded/b9af73325528959212d2c665099d4e1f.jpg)
![Foto de Hackensack University Medical Center](/img/noimage_org.png)
Hackensack University Medical Center
Hackensack, Estados UnidosPublicaciones en colaboración con investigadores/as de Hackensack University Medical Center (3)
2022
-
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33
-
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494
2021
-
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Journal of Hematology and Oncology